Analyst Price Target is $3.50
▲ +473.77% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for X4 Pharmaceuticals in the last 3 months. The average price target is $3.50, with a high forecast of $5.00 and a low forecast of $1.50. The average price target represents a 473.77% upside from the last price of $0.61.
Current Consensus is
Buy
The current consensus among 3 contributing investment analysts is to buy stock in X4 Pharmaceuticals. This rating changed within the last month from a Moderate Buy consensus rating.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Read More
